Company intelligence / Profile preview
Sprint Bioscience
- Ownership
- Public · SPRINT
- Employees
- ~38
- Development stage
- Preclinical
Overview
Sprint Bioscience specializes in early-stage oncology drug development using a fragment-based approach. Its programs are typically outlicensed to global pharmaceutical partners during the preclinical phase. The company has developed several novel small molecule candidates targeting cancer and tumor metabolism pathways but does not have clinical results published as its assets are licensed before entering human trials.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small molecules (fragment-based drug discovery)[6]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $42.7M
- Total revenue
- $16.9M
- Enterprise value
- $33.2M
Beyond the preview
Go deeper on Sprint Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sprint Bioscience.